IRCT20170614034526N3
Completed
未知
Efficacy and tolerability of Sofosbuvir and Daclatasvir for treatment of Hepatitis C genotype 3 in patients undergoing hemodialysis- A Prospective interventional clinical trial
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Jinnah Hospital, Lahore
- Enrollment
- 36
- Status
- Completed
- Last Updated
- 7 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Male \& Female (non\-pregnant)
- •being at the age of 18 years and over
- •End stage renal disease patients undergoing maintenance hemodialysis detected with HCV RNA by PCR.
Exclusion Criteria
- •Patients having co\-infection with HBV, HIV.
- •Patients with decompensated cirrhosis and terminal illness.
- •Patients hypersensitive to any of the ingredients of treatment drugs.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Safety And Effectiveness Of Sofosbuvir And Daclatasvir In Patients Who Have Thalassemia With Hepatitis C Virus Infection And Who Are 6 years To 18 Years OldHealth Condition 1: B182- Chronic viral hepatitis CHealth Condition 2: D56- ThalassemiaCTRI/2020/06/025910Riten Kumar Samadder70
Recruiting
Phase 2
Efficacy & Safety of Sofosbuvir/Daclatasvir treatment in COVID-19: A randomized, controlled studyCOVID-19SARS-nCoV-2 infectionDRKS00022203PHARCO CORPORATE90
Completed
Phase 3
Efficacy of Daclatasvir and Sofosbuvir (Sovodak) in patients with HCVIRCT20080901001155N30Rasht University of Medical Sciences16
Completed
Phase 2
Comparison of the effect of Sofosbuvir + Daclatasvir (Sovodac) and Ribavirin in Covid-19COVID-19.2019-nCOV diseaseU07.1IRCT20200324046850N2Abadan University of Medical Sciences62
Completed
Phase 3
Hepatitis C Treatment in a Community-based SettingIRCT20170213032547N1Kerman University of Medical Sciences110